CTOs on the Move

St. Joseph of the Pines Health System

www.sjp.org

 
St. Joseph of the Pines Health System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. St. Joseph of the Pines Health System is based in Newark, NJ. You can find more information on St. Joseph of the Pines Health System at www.sjp.org
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sjp.org
  • 100 Mulberry St
    Newark, NJ USA '07102
  • Phone: 910.246.1000

Executives

Name Title Contact Details

Similar Companies

Psymed Inc

Psymed Inc is a Valley Forge, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Touchstone Health Partnership

Touchstone Health Partnership is a White Plains, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Barenburg Eye

Barenburg Eye is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Modern Vascular Management

Modern Vascular is a group of healthcare companies headquartered in Phoenix, AZ. Modern Vascular clinics specialize in the treatment of peripheral artery disease (PAD) through infrapopliteal, inframalleolar, and pedal endovascular arterial reconstruction. Most patients report reduced pain, rapid wound healing, and a better quality of life post procedure. Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients. Modern Vascular now operates and manages thirteen clinics across AZ, CO, MS, NM, TX, VA

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.